AAOS Clincal Practice Guidelines Unit i v1.0_ 092311
PREVENTING VENOUS THROMBOEMBOLIC
DISEASE IN PATIENTS UNDERGOING ELECTIVE HIP
AND KNEE ARTHROPLASTY
EVIDENCE-BASED
GUIDELINE
AND EVIDENCE REPORT
AAOS Clincal Practice Guidelines Unit ii v1.0_ 092311
Disclaimer
This clinical guideline was developed by an AAOS physician volunteer Work Group and experts
in systematic reviews. It is provided as an educational tool based on an assessment of the current
scientific and clinical information and accepted approaches to treatment. The recommendations
in this guideline are not intended to be a fixed protocol as some patients may require more or less
treatment or different means of diagnosis. Patients seen in clinical practice may not be the same
as those found in a clinical trial. Patient care and treatment should always be based on a
clinician’s independent medical judgment given the individual clinical circumstances.
Disclosure Requirement
In accordance with AAOS policy, all individuals whose names appear as authors or contributors
to this clinical practice guideline filed a disclosure statement as part of the submission process.
All panel members provided full disclosure of potential conflicts of interest prior to beginning
work on the recommendations contained within this clinical practice guideline.
Funding Source
The American Academy of Orthopaedic Surgeons exclusively funded this clinical practice
guideline. The Academy received no funding from outside commercial sources to support the
development of this document.
FDA Clearance
Some drugs or medical devices referenced or described in this clinical practice guideline may not
have been cleared by the Food and Drug Administration (FDA) or may have been cleared for a
specific use only. The FDA has stated that it is the responsibility of the physician to determine
the FDA clearance status of each drug or device he or she wishes to use in clinical practice.
Copyright
All rights reserved
VTE_full_guideline.pdf